List of Excipients in Branded Drug ILARIS

ILARIS Excipient Strategy and Commercial Opportunities for Canakinumab

Last updated: August 22, 2026

ILARIS is Novartis’ brand for canakinumab, a fully human monoclonal antibody that selectively binds interleukin-1 beta. Its commercial opportunity is concentrated in rare autoinflammatory diseases, where long dosing intervals and limited alternatives support premium pricing. The current excipient strategy is conservative: a sucrose-histidine-polysorbate 80 system in a single-dose injectable presentation. The main opportunities are improved convenience, reduced administration burden, lifecycle differentiation, and supply-chain resilience rather than a simple reformulation with a new buffer.

What excipients are used in ILARIS?

ILARIS uses a conventional liquid biologic formulation after reconstitution. The United States product is supplied as a 150 mg lyophilized powder in a single-dose vial. The formulation contains canakinumab with sucrose, histidine, histidine hydrochloride monohydrate, and polysorbate 80. The product is reconstituted with sterile water before subcutaneous administration.[1]

Formulation element	Role in ILARIS	Commercial relevance
Canakinumab	Active monoclonal antibody	Targets IL-1 beta
Sucrose	Stabilizes protein structure during freezing and drying	Supports lyophilized shelf life
Histidine and histidine hydrochloride	Buffer system	Helps control pH during storage
Polysorbate 80	Surfactant	Reduces interface-related aggregation and surface adsorption
Sterile water for injection	Reconstitution vehicle	Adds preparation time and handling requirements

The excipient system is consistent with established monoclonal-antibody formulation practice. Sucrose supports the freeze-dried cake, histidine provides pH control, and polysorbate 80 limits aggregation caused by contact with vial and syringe surfaces.

Why is ILARIS supplied as a lyophilized product?

A lyophilized presentation can improve long-term protein stability and reduce dependence on refrigerated liquid stability. That tradeoff increases preparation complexity. Healthcare personnel must reconstitute the product, inspect the solution, and administer it subcutaneously. The European product information similarly identifies a powder for solution for injection and requires reconstitution before use.[2]

For a chronic rare-disease product, the commercial penalty is meaningful. Patients may receive treatment every four weeks or every eight weeks, but each administration still involves preparation steps that could be removed through a ready-to-use liquid or prefilled device.

What clinical and commercial characteristics shape the excipient strategy?

ILARIS is approved in the United States for cryopyrin-associated periodic syndromes, including familial cold autoinflammatory syndrome and Muckle-Wells syndrome; tumor necrosis factor receptor-associated periodic syndrome; mevalonate kinase-associated periodic fever syndrome; and systemic juvenile idiopathic arthritis.[1]

The dosing schedule varies by indication:

Indication	Typical U.S. dosing	Administration interval
CAPS	150 mg or 2 mg/kg in eligible patients	Every 8 weeks
TRAPS	150 mg or 2 mg/kg	Every 4 weeks
HIDS/MKD	150 mg or 2 mg/kg	Every 4 weeks
Systemic JIA	4 mg/kg, up to 300 mg	Every 4 weeks

The long interval is commercially favorable. It reduces annual injection frequency compared with many biologics and creates a basis for premium reimbursement. It also increases the value of dose accuracy, storage flexibility, preparation simplicity, and patient or caregiver administration.

The principal formulation challenge is not merely antibody concentration. It is balancing:

• protein stability during storage;
• reconstitution time;
• injection volume;
• viscosity at higher concentration;
• subcutaneous tolerability;
• particulate control;
• container-closure compatibility;
• polysorbate degradation and oxidation;
• global cold-chain requirements.

What formulation opportunities exist for ILARIS?

Ready-to-use liquid formulation

The highest-value opportunity is a stable liquid canakinumab presentation that eliminates reconstitution. A ready-to-use vial, prefilled syringe, or autoinjector could reduce pharmacy labor and administration errors.

A liquid formulation would need to address several risks:

1. Long-term aggregation and particle formation.
2. Oxidation or hydrolysis of polysorbate 80.
3. Protein adsorption to the container or device.
4. Increased viscosity at higher concentration.
5. Reduced stability under temperature excursions.
6. Compatibility with silicone oil, elastomers, needles, and device adhesives.

A liquid version could retain sucrose and histidine while optimizing surfactant concentration, pH, ionic strength, and protein concentration. It could also use a different surfactant system, such as polysorbate 20 or poloxamer 188, if comparative stability and immunogenicity data support the change.

Prefilled syringe and autoinjector

A device presentation has greater commercial value than a vial if it enables administration outside a hospital or specialist clinic. The target populations include children with systemic JIA, adolescents, caregivers managing periodic fever syndromes, and patients in remote locations.

The technical barriers include:

• delivery of a high-protein-dose solution through a fine-gauge needle;
• acceptable injection force;
• control of dose accuracy;
• device stability over the product shelf life;
• low extractables and leachables;
• prevention of clogging or incomplete delivery;
• usability for pediatric and caregiver populations.

The current 150 mg dose is compatible with a single-dose device in principle. The 300 mg maximum dose for systemic JIA may require two injections or a higher-strength presentation. A higher-concentration product could reduce injection burden but would increase viscosity and formulation risk.

Excipient substitution

Polysorbate 80 is widely used, but surfactant degradation is a recognized development issue for biologics. Oxidized or hydrolyzed surfactant can contribute to particles, protein oxidation, and changes in product quality. A lifecycle program could evaluate polysorbate 20, poloxamer 188, or alternative surfactant systems.

The commercial value of substitution would depend on measurable outcomes:

• longer shelf life;
• better stability after agitation;
• improved tolerance to temperature excursions;
• lower particulate burden;
• compatibility with a prefilled device;
• reduced dependence on a single excipient supplier.

Excipient substitution alone is unlikely to create a durable market advantage unless it enables a new presentation or a meaningful reduction in total cost of ownership.

Higher-concentration formulation

A 150 mg/mL product is already relatively concentrated for a monoclonal antibody. A higher-strength formulation could reduce injection volume, but the benefit may be limited if the commercial dose remains 150 mg and the product is administered by healthcare professionals.

Higher concentration can increase viscosity, aggregation risk, opalescence, and injection force. It can also complicate autoinjector design. The economic case is strongest when a higher concentration enables a practical single-injection 300 mg dose or materially improves home administration.

What patents protect ILARIS formulations and delivery systems?

ILARIS is a biologic licensed through an FDA biologics license application, not a conventional small-molecule NDA. It therefore does not have the same Orange Book patent-listing framework used for most small-molecule drugs.[3]

Does ILARIS have Orange Book listings?

No conventional Orange Book listing should be expected for canakinumab because biologics are generally tracked through the FDA’s Purple Book rather than the Orange Book. The Purple Book identifies licensed biological products and reference-product information relevant to biosimilar and interchangeable-product competition.[4]

Do Paragraph IV challenges apply to ILARIS?

Paragraph IV litigation is a Hatch-Waxman mechanism for small-molecule abbreviated new drug applications. It is not the normal pathway for a canakinumab biosimilar. A biosimilar applicant would proceed under the Public Health Service Act, with patent disclosures and litigation governed primarily by the Biologics Price Competition and Innovation Act framework.[5]

What types of patents are commercially relevant?

The most relevant patent categories are:

• antibody composition and binding-site claims;
• methods of treating IL-1 beta-mediated diseases;
• dosing regimens for CAPS, TRAPS, HIDS/MKD, and systemic JIA;
• lyophilized formulations;
• liquid formulations;
• excipient combinations;
• high-concentration presentations;
• prefilled syringes and autoinjectors;
• manufacturing and purification methods.

A formulation patent can have strategic value after core antibody claims weaken, but only if it covers a commercially necessary product configuration. A narrow patent covering a specific pH, surfactant concentration, or excipient ratio may be easier to design around than a broad composition-of-matter claim.

When does ILARIS lose exclusivity?

ILARIS received its first U.S. approval in 2009. The 12-year reference-product exclusivity period applicable to biologics has therefore expired.[1,5] Patent expiration dates remain jurisdiction-specific and depend on the claims, patent-term adjustment, patent-term extension, terminal disclaimers, continuations, and litigation outcomes.

The key commercial point is that regulatory exclusivity and patent exclusivity are separate:

Protection	ILARIS relevance
U.S. biologic reference-product exclusivity	Expired based on the 2009 first licensure date
Orange Book listing	Not the applicable framework
Purple Book reference-product status	Applicable
Paragraph IV certification	Not the standard biosimilar mechanism
Formulation patents	May support later expiry for specific presentations
Method-of-use patents	May affect labeled-indication competition
Manufacturing patents	May raise development and supply barriers

The absence of active reference-product exclusivity does not guarantee immediate biosimilar entry. Canakinumab is a complex, highly characterized monoclonal antibody with a small rare-disease market. Development economics, clinical comparability, manufacturing scale, and reimbursement can delay competition.

What generic and biosimilar entry risks exist for ILARIS?

A conventional generic is not the relevant competitive threat. The principal risk is a canakinumab biosimilar or a follow-on biologic.

Biosimilar development barriers

A prospective competitor would need to establish high similarity in:

• primary amino-acid sequence;
• higher-order structure;
• glycosylation;
• charge and size variants;
• aggregation profile;
• potency and IL-1 beta binding;
• pharmacokinetics;
• immunogenicity;
• product-related impurities.

The product’s orphan and specialty indications reduce the addressable market. That can deter investment, but it can also attract focused biosimilar developers seeking premium pricing with limited competition.

Commercial launch scenarios

Scenario	Likely effect
No approved biosimilar	Continued premium pricing and strong value for convenience reformulation
One biosimilar	Moderate price pressure, especially in hospital and payer channels
Multiple biosimilars	Greater rebate pressure and possible formulary substitution
New liquid or device presentation	Differentiated product may retain share despite biosimilar entry
Pediatric autoinjector	Potentially defensible niche if supported by usability and adherence data

The most exposed segment is institutional purchasing. The least exposed segment is likely specialist-managed, pediatric, or highly individualized care where continuity and administration convenience carry more weight.

Which companies could challenge ILARIS?

The competitive field includes established biosimilar manufacturers with monoclonal-antibody capabilities, regional biologics companies, and specialty pharmaceutical firms. Potentially relevant capabilities include cell-line development, analytical comparability, sterile fill-finish, device combination products, and rare-disease commercialization.

No company should be treated as an active canakinumab challenger without evidence of a disclosed development program, regulatory filing, patent action, or clinical trial. The practical competitive screen should monitor:

• Purple Book additions;
• clinical trial registrations involving canakinumab follow-on products;
• patent litigation filings;
• regulatory designations;
• manufacturing-site disclosures;
• licensing transactions;
• payer formulary decisions.

How strong is the ILARIS patent estate?

The patent estate is strongest where it protects the antibody, a required dose regimen, or a commercially necessary delivery format. It is weaker where it relies only on narrow excipient ranges that competitors can avoid through alternative buffers or surfactants.

A formulation strategy can improve patent durability by combining:

• defined canakinumab concentration;
• specified pH range;
• selected stabilizer and surfactant;
• low particulate limits;
• liquid stability;
• device compatibility;
• storage and administration conditions.

Claims that link formulation composition to measurable stability or usability advantages are more commercially valuable than claims that merely recite routine excipient combinations.

What licensing deals could create ILARIS-related opportunities?

The most credible licensing opportunities are likely to involve enabling technology rather than the active antibody itself. Relevant assets include:

• high-concentration antibody formulations;
• low-viscosity protein systems;
• surfactant-stabilized liquid biologics;
• prefilled syringe platforms;
• autoinjectors for viscous biologics;
• low-temperature or room-temperature storage technology;
• pediatric delivery systems;
• biosimilar analytical platforms.

For Novartis, an external technology could support a lifecycle product without changing the canakinumab molecule. For a technology company, a validated platform could support a co-development, formulation license, device supply agreement, or regional commercialization arrangement.

What FDA regulatory issues affect an ILARIS reformulation?

A new excipient system or dosage form would usually require a supplemental biologics application if developed by the reference-product sponsor. The submission would need to address product quality, comparability, stability, container closure, device performance, extractables and leachables, and human factors for an autoinjector or prefilled syringe.[1,6]

A biosimilar sponsor would face a separate analytical and clinical development program. A formulation materially different from the reference product could complicate the demonstration of similarity, even if the active antibody remains unchanged.

The strongest regulatory strategy is generally a formulation change that preserves the antibody, concentration, route, and dose while improving stability or administration. A new presentation that changes the injection device may require combination-product review and usability evidence.

Key Takeaways

• ILARIS uses a lyophilized canakinumab formulation containing sucrose, histidine, histidine hydrochloride monohydrate, and polysorbate 80.
• The largest commercial opportunity is a ready-to-use liquid, prefilled syringe, or autoinjector.
• Excipient substitution has value when it enables longer shelf life, lower particulate formation, better device compatibility, or reduced cold-chain dependence.
• U.S. biologic exclusivity from the 2009 first licensure has expired.
• Orange Book and Paragraph IV analysis is not the correct framework for canakinumab; Purple Book and BPCIA processes are more relevant.
• Biosimilar entry is technically feasible but commercially constrained by rare-disease market size and complex analytical requirements.
• Formulation patents are most valuable when they protect a product configuration that competitors cannot easily design around.
• Device and formulation licensing may provide stronger commercial leverage than an excipient-only patent.

FAQs About ILARIS Excipient and Commercial Strategy

Can ILARIS be reformulated as a liquid injection?

Yes. A liquid canakinumab formulation is technically plausible, but it would require extensive stability, aggregation, particulate, container-closure, and device-compatibility work.

Which excipient is most important in ILARIS?

Sucrose supports protein stabilization during lyophilization, while histidine controls pH and polysorbate 80 protects against interface-related aggregation. The commercial importance depends on the target presentation.

Is ILARIS vulnerable to a generic drug?

No conventional generic pathway applies. The relevant threat is a canakinumab biosimilar or follow-on biologic.

Would a prefilled ILARIS syringe improve commercial positioning?

Yes. It could reduce reconstitution steps, administration time, preparation errors, and clinic labor. The value would be greatest in pediatric and home-administration settings.

Can a competitor avoid ILARIS formulation patents?

Often, yes, if the claims are limited to particular excipient ratios, pH ranges, or presentation details. The ease of design-around depends on the scope and validity of each patent family.

References

1. U.S. Food and Drug Administration. (2024). ILARIS (canakinumab) prescribing information. Novartis Pharmaceuticals Corporation.
2. European Medicines Agency. (2024). Ilaris: EPAR product information.
3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations.
4. U.S. Food and Drug Administration. (2024). Purple Book: Database of licensed biological products.
5. U.S. Congress. (2010). Patient Protection and Affordable Care Act, Section 7002: Biosimilar biological products.
6. U.S. Food and Drug Administration. (2015). Q5E comparability of biotechnological/biological products: Guidance for industry.